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ABSTRACT
Objectives: Besides hypoxaemia severity, heart rate variability has been linked to cognitive decline in
obstructive sleep apnoea (OSA) patients. Thus, our aim was to examine whether the frequency domain
features of a nocturnal photoplethysmogram (PPG) can be linked to poor performance in the
psychomotor vigilance task (PVT).
Methods: PPG signals from 567 suspected OSA patients, extracted from Type 1 diagnostic
polysomnography, and corresponding results of PVT were retrospectively examined. The frequency
content of complete PPGs was determined, and analyses were conducted separately for men (n=327) and
women (n=240). Patients were grouped into PVT performance quartiles based on the number of lapses
(reaction times ⩾500 ms) and within-test variation in reaction times. The best-performing (Q1) and worst-
performing (Q4) quartiles were compared due the lack of clinical thresholds in PVT.
Results: We found that the increase in arterial pulsation frequency (APF) in both men and women was
associated with a higher number of lapses. Higher APF was also associated with higher within-test
variation in men, but not in women. Median APF (β=0.27, p=0.01), time spent under 90% saturation
(β=0.05, p<0.01), female sex (β=1.29, p<0.01), older age (β=0.03, p<0.01) and subjective sleepiness (β=0.07,
p<0.01) were significant predictors of belonging to Q4 based on lapses. Only female sex (β=0.75, p<0.01)
and depression (β=0.91, p<0.02) were significant predictors of belonging to Q4 based on the within-test
variation.
Conclusions: In conclusion, increased APF in PPG provides a possible polysomnography indicator for
deteriorated vigilance especially in male OSA patients. This finding highlights the connection between
cardiorespiratory regulation, vigilance and OSA. However, our results indicate substantial sex-dependent
differences that warrant further prospective studies.
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Obstructive sleep apnoea (OSA), characterised by repeated breathing cessations, intermittent hypoxaemia
and arousals from sleep, is one of the most prevalent sleep disorders [1]. It has a strong association with
various comorbid conditions, such as cerebrovascular, cardiovascular, metabolic and neurological diseases
[2, 3]. It has also been linked to deteriorated outcomes in different domains of cognitive functioning [4],
for example in the psychomotor vigilance task (PVT) [5]. PVT is a measure of vigilance and the ability to
sustain attention. Due to the low learning effect, low-labour test protocol and minimal subjectivity, PVT is
recognised as a reliable test to evaluate neurocognitive performance [6].
Previous studies show that severe intermittent hypoxaemia, quantified by the duration, depth and
frequency of oxygen desaturations, is associated with daytime sleepiness and cognitive decline in OSA
patients [7–10]. However, desaturation metrics and other parameters quantifying the severity of OSA are
not fully capable of explaining the impaired performance in PVT in OSA patients having shallow and
short desaturations [10]. This suggests that additional factors could explain the associations between OSA
and poor PVT performance. Therefore, novel biomarkers could be extremely useful for patients with
relatively stable nocturnal oxygenation despite repetitive breathing cessations.
Nocturnal intermittent hypoxaemia can be quantified with a pulse oximeter. It provides noninvasively
information on blood oxygen saturation (SpO2) based on the absorption of red and infrared light in the
blood volume [11]. In sleep medicine, the photoplethysmogram (PPG) derived from the original
absorption signal is less used than SpO2 [12]. However, PPG has great potential in the long-term
monitoring of cardiorespiratory function, as it is an unobtrusive measurement technique that contains
information on the amplitude and frequency of the arterial pulsations alongside derived SpO2 [11, 12].
Therefore, frequency domain investigations of the PPG could be beneficial as it combines the information
of amplitude and frequency changes without peak detection from the PPG, which has high uncertainties
compared to ECG-based R-peak detection [13].
OSA induces abnormal heart rate variability during sleep due to apnoeas and hypopnoeas causing
desaturations and arousals from sleep [14]. Moreover, OSA disrupts normal sleep cycles and reduces the
time spent in deeper stages of sleep [3]. Deeper stages of sleep are associated with higher parasympathetic
drive and lower heart rate; conversely OSA is associated with high nocturnal sympathetic drive and higher
heart rates [3, 15]. Furthermore, non-dipping nocturnal heart rate and increased resting heart rate in
24-hour Holter ECG have been linked to worsened cognitive performance [16]. As PPG is shown to be a
reliable surrogate for ECG [17], we hypothesise that the information content of the PPG signal can be
linked to poor performance in PVT.
Thus, the main aim of this study is to examine whether the frequency domain features of nocturnal PPG
can be linked to deteriorated vigilance in OSA patients. In addition, we aim to examine whether larger
within-test variation in reaction times is associated with spectral features of PPG. As earlier literature
shows that PVT performance is highly sex-dependent [10, 18], we perform the analyses separately for men
and women.
Methods
The initial clinical cohort comprised 912 consecutive suspected OSA patients undergoing
polysomnography (PSG) in the Sleep Disorders Center of Princess Alexandra Hospital (Brisbane,
Australia). The Institutional Human Research Ethics Committee of the Princess Alexandra Hospital
approved the retrospective data collection (HREC/16/QPAH/021 and LNR/2019/QMS/54313). The cohort
comprised all patients from the normal clinical inflow of suspected OSA patients between 2015 and 2017.
From the initial population, 567 patients were selected into the studied population based on the following
inclusion criteria: 1) complete demographic and comorbidity information; 2) successful PSG and
completed PVT; 3) apnoea–hypopnoea index (AHI) ⩾5; and 4) total sleep time in PSG ⩾4 h. PSG
recordings were conducted and scored with the Compumedics Grael acquisition system and Compumedics
ProFusion PSG 4 software (Compumedics, Abbotsford, Australia). PSG recordings were manually scored
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by experienced sleep technicians; all scorings were conducted in conformity with the American Academy
of Sleep Medicine (AASM) 2012 guidelines [19]. None of the included patients had central sleep apnoea,
i.e. the proportion of central apnoeas did not exceed 50% of the total number of apnoeas.
The PPG signal analysis protocol is illustrated in figure 1. First, complete PPG signals, measured with a
transmissive Nonin Xpod 3011 finger pulse oximeter, were exported from each patient. Next, PPG signals
were decimated from the original 256 Hz sampling frequency to 64 Hz with an anti-aliasing Chebyshev
filter to reduce computational load. Signals were further filtered using an 8th order Chebyshev Type 2
lowpass-filter with a 60 dB stop-band ripple threshold and 6 Hz cut-off to eliminate unphysiological noise
from decimated PPG. Signals were divided into 512 segments to enable comparison between spectrograms
and to retain the temporal changes in frequency content throughout the night (figure 1). For all patients,
the median segment length was 52.2 s, varying from a minimum of 38.7 s to a maximum of 68.2 s. For all
segments, the power spectrum was computed using Welch’s periodogram with eight partitions and 50%
overlap utilising the Hamming window to reduce the side-lobe leaking effect. Power spectrums were
analysed in a physiologically relevant arterial pulsation band between 0.5 and 4 Hz corresponding to heart
rates between 30 and 240 bpm. Power spectrums were further converted into spectrogram images, with the
x-axis representing the corresponding segment of the night and y-axis corresponding to PPG signal
frequency content (figure 1). The power of each frequency is displayed via a colour map in the
spectrogram image.
The PVTs were conducted as part of standard clinical protocol utilised in Princess Alexandra Hospital.
PVTs were timed between 19:00 and 21:00 h on the evening prior to the PSG study. The Psychology
Experiment Building Language (PEBL) PVT programme was used on an ASUS Transformer Pad with an
attached keyboard [20]. PVT was performed using a 10-minute protocol. The protocol comprises 121
single-trial visual stimuli occurring randomly at 2 to 10 s intervals. Patients were instructed to use the
index finger or thumb of their dominant hand and press the response button as soon as they saw the
stimulus on the screen. Full trial series were exported from every patient and data on the PVT
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FIGURE 1 Illustrative description of the decomposition of photoplethysmogram (PPG) signal. The complete preprocessed PPG signal is first
divided into 512 segments. All segments are equal in length except the last segment, the length of which is the number of remaining sampling
points if the signal is not divisible by 512. The frequency content within the nth segment is determined using Welch’s method: the segment is
divided into eight parts with a 50% overlap. For every part, a power spectral density estimate is computed and then averaged. After this procedure
is completed for every 512 segments, they are ordered into a spectrogram image for temporal interpretation of the frequency content within the
signal.
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computed. In-test variation in repeated reaction times was quantified using Sample Entropy [21]. Before
Sample Entropy analyses, the PVT trial series was normalised to achieve zero-mean with a standard
deviation of 1 to reduce the baseline effect. The Sample Entropy estimates were computed using the
following parameter settings: a template vector with a length of 5 and a distance-tolerance threshold of 0.4.
The studied patient population was first divided into men and women. After separation, men and women
were grouped to quartiles based on PVT performance as PVT does not have standard clinical thresholds
for outcomes. Based on preliminary analyses, differences between quartiles 1, 2 and 3 were relatively small
in men. In women, the difference between quartiles 1 and 2 and between quartiles 3 and 4 was small. For
clarity and to achieve more coherent and informative results, we decided only to present the differences in
PPG frequency content in patients with normal and notably impaired vigilance. Thus, only the best (Q1)
and the worst (Q4) quartiles based on the number of lapses and Sample Entropy are compared in detail.
All reported comorbidities are based on medical records and interviews in a sleep clinic. Group-median
spectrograms were defined for Q1 and Q4. Stationary group-median power spectrums were extracted from
the spectrogram. In addition, peak-power frequencies indicating the dominant arterial pulsation frequency
(APF) were computed from individual spectrograms and from the median spectrograms of Q1 and Q4.
For plotting purposes, the APF curves were smoothed via a moving average filter having a 25-point
window. The cumulative distribution function (CDF) of APF in the peak-frequency curve was computed
from median spectrograms together with 95% confidence intervals via Kaplan–Meier estimates. Statistical
difference of cumulative distribution functions between Q1 and Q4 was computed using a two-sided
Kolmogorov–Smirnov test. To evaluate the possible confounding effect of reported comorbidities and to
analyse multivariate models’ sensitivity and specificity, stepwise logistic regression with Bayesian
Information Criterion (BIC) was used within the whole population to assess the probability of belonging
to Q4. The model was adjusted for sex, age, body mass index, chronic obstructive pulmonary disease
(COPD), hypertension, depression, smoking status and subjective sleepiness assessed with the Epworth
Sleepiness Scale (ESS). Sleep stage distributions and parameters describing OSA severity (table 2) were
investigated by inputting them to regression models separately. After estimating the most significant
predictor variables, their performance was evaluated by computing receiver operating characteristic (ROC)
curves and corresponding area under the curve (AUC). All data analyses and statistical testing were
performed using MatLab (ver. 2018b, MathWorks Inc., Natick, MA, USA) with custom-made functions
and functions in Statistics and Machine Learning Toolbox and Signal Processing Toolbox.
Results
Differences in demographics, comorbidities and PSG parameters
The PVT performance data are presented in table 1. Demographic, comorbidity and PSG data of Q1 and
Q4 with respect to both PVT outcome variables are presented in table 2. The comparison between men
and women shows that women have a significantly higher number of lapses and consistently longer
reaction times than men (table 1). Conversely, women suffer from substantially less severe OSA based on
AHI, oxygen desaturation index and t90% (table 2). In addition, a substantially lower degree of sleep
disruption is seen women, having a higher amount of N3 sleep, a lower amount of N1 sleep and a lower
arousal index (table 2).
Subgroup analysis between men in Q1 and Q4 based on lapses revealed that patients belonging to Q4 were
significantly older (p=0.02) and had shorter total sleep time in PSG (p=0.02) (table 2). Q4 tended to
comprise a higher number of hypertensive (43.8% versus 29.6%, p=0.05) and depressed (16.3% versus
TABLE 1 Psychomotor vigilance task performance data in all patients (n=567), in men (n=327)
and in women (n=240)
All patients Male OSA patients Female OSA patients
Median RT ms 378.0 (341.0–440.8) 362.4 (332.6–410.8) 405.1 (363.0–477.0)
RRT ms−1 2.6 (2.2–2.9) 2.7 (2.4–3.0) 2.4 (2.1–2.7)
Slowest 10% RT ms 676.0 (544.3–1025.0) 622.0 (518.3–910.5) 753.5 (578.5–1221.0)
Fastest 10% RT ms 297.0 (277.4–334.2) 289.0 (272.5–317.2) 313.0 (285.5–352.0)
Lapses 13 (5–35) 10 (4–21) 19 (9–51)
Sample Entropy 0.31 (0.12–0.71) 0.22 (0.11–0.66) 0.44 (0.16–0.80)
All values are presented as the median (interquartile range). All performance metrics differed significantly
between men and women based on Wilcoxon rank-sum test. OSA: obstructive sleep apnoea; RT: reaction
time; RRT: mean reciprocal reaction time.
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TABLE 2 Demographic, polysomnographic (PSG) and comorbidity data and statistical analyses between the best-performing (Q1) and worst-performing (Q4)
quartiles based on lapses and sample entropy of reaction times in a psychomotor vigilance task
Male OSA patients# Female OSA patients¶
Lapses Sample Entropy Lapses Sample Entropy
Q1 (<4) Q4 (>21) Q1 (<0.105) Q4 (>0.656) Q1 (<9) Q4 (>51) Q1 (<0.163) Q4 (>0.800)
Demographic parameters
Patients n 88 80 82 82 66 59 60 60
Age years 51.1 (40.7–61.7) 56.9 (48.4–67.1) 52.8 (40.5–65.3) 55.4 (44.9–62.2) 54.3 (44.7–60.3) 58.8 (50.3–64.8) 54.1 (45.1–62.3) 55.9 (45.5–62.2)
BMI kg·m−2 32.9 (28.7–37.8) 34.7 (29.8–39.5) 34.5 (30.9–40.4) 33.7 (29.5–37.8) 37.0 (32.3–44.4) 36.0 (31.8–47.1) 38.7 (32.5–45.8) 36.0 (29.0–42.7)
Comorbidities
COPD 6 (6.8) 8 (10.0) 5 (6.1) 5 (6.1) 5 (7.6) 8 (13.6) 5 (8.3) 6 (10.0)
Hypertension 26 (29.6) 35 (43.8) 32 (39.0) 30 (36.6) 22 (33.3) 29 (49.2) 22 (36.7) 22 (36.7)
Depression 8 (9.1) 13 (16.3) 6 (7.3) 13 (15.9) 14 (21.2) 15 (25.4) 10 (16.7) 14 (23.3)
Smokers 13 (14.8) 13 (16.3) 14 (17.1) 12 (14.6) 6 (9.1) 10 (17.0) 8 (13.3) 9 (15.0)
ESS score 9 (6–15) 10 (6–14) 8 (5–12) 10 (5–13) 9 (6–12) 13 (6–18) 11 (6–15) 9 (5–13)
PSG parameters
Total sleep time h 5.4 (4.8–6.1) 4.9 (4.5–5.8) 5.3 (4.7–6.1) 5.2 (4.6–5.9) 5.4 (6.0–4.7) 5.6 (4.9–6.4) 5.6 (5.0–6.2) 5.7 (4.9–6.3)
N1 % 15.5 (10.6–23.8) 14.1 (8.7–21.5) 15.4 (9.3–22.1) 14.7 (9.6–25.7) 7.9 (5.7–10.8) 8.1 (5.8–12.8) 8.0 (5.6–13.3) 8.9 (6.0–14.4)
N2 % 47.3 (42.3–52.9) 49.5 (42.6–57.9) 48.2 (42.2–56.1) 45.8 (39.6–54.1) 47.1 (41.4–53.4) 49.0 (40.3–61.2) 47.3 (41.5–53.4) 49.2 (40.4–53.0)
N3 % 16.2 (7.4–23.1) 14.9 (5.0–24.2) 14.6 (7.7–23.8) 15.1 (9.4–23.4) 24.2 (17.3–29.9) 21.6 (12.0–29.3) 23.0 (17.4–29.3) 20.6 (15.2–29.4)
REM % 18.0 (13.7–22.4) 17.0 (12.9–20.6) 18.8 (14.7–22.4) 15.8 (11.6–22.8) 18.5 (12.9–23.3) 19.1 (12.9–22.5) 19.0 (13.0–21.8) 19.2 (12.1–24.8)
AI events·h−1 33.5 (22.4–46.8) 31.6 (22.1–45.6) 31.5 (19.5–42.9) 35.1 (23.1–47.2) 21.3 (30.4–16.1) 24.3 (15.5–33.8) 23.1 (16.0–32.0) 22.7 (18.3–32.4)
AHI events·h−1 29.8 (13.4–49.2) 28.6 (19.9–44.3) 25.0 (15.3–42.3) 28.8 (18.9–53.8) 16.0 (9.3–29.7) 15.8 (10.1–37.7) 17.6 (10.1–27.2) 15.0 (8.9–31.0)
ODI events·h−1 20.4 (6.7–32.9) 21.0 (9.9–37.4) 16.8 (7.5–30.1) 20.0 (8.3–36.6) 11.5 (5.2–26.8) 13.3 (5.6–25.6) 12.5 (5.1–24.6) 9.3 (4.0–21.6)
t90% min 6.8 (1.3–46.8) 15.6 (1.7–98.2) 12.4 (1.4–44.7) 8.9 (0.8–50.4) 4.6 (0.8–32.8) 11.5 (1.0–63.5) 4.3 (0.5–42.8) 3.4 (0.3–45.6)
mDD % 4.9 (4.1–7.4) 5.3 (4.4–7.5) 5.6 (4.1–8.0) 5.1 (4.1–6.6) 5.0 (4.1–6.4) 5.1 (4.3–6.0) 4.7 (4.0–6.2) 4.9 (4.1–6.0)
Data are presented as median (interquartile range) or n (%), unless otherwise stated. OSA: obstructive sleep apnoea; BMI: body mass index; COPD: chronic obstructive pulmonary
disease; ESS: Epworth Sleepiness Scale; N1–N3: non-rapid eye movement sleep stages 1–3; REM: rapid eye movement sleep; AI: arousal index; AHI: apnoea–hypopnoea index;
ODI: oxygen desaturation index; t90%: time spent under 90% oxygenation; mDD: median desaturation depth.
#: n=327; ¶: n=240. Bolded values indicate statistical difference (p<0.05)















9.1%, p=0.16) patients compared to Q1. In addition, patients in lapses Q4 had a trend towards more
severe nocturnal hypoxaemia seen as increased t90% (15.6 versus 6.8 min, p=0.12). In Sample Entropy
comparison, Q1 and Q4 were highly similar based on demographics, PSG parameters and comorbidities
(table 2).
Female patients in lapses Q4 were subjectively sleepier (ESS: 9 versus 13, p=0.01) compared to Q1 (table 2).
Q4 tended to be older (p=0.06), slept longer (p=0.06), and were more likely to have hypertension (p=0.07)
compared to Q1. No difference between Sample Entropy Q1 and Q4 were observed (table 2).
Frequency domain analysis of the PPG signal
A comparison of male OSA patients in Q1 and Q4 based on lapse count showed significantly higher APF
in Q4 (figure 2a and 2b). The median power spectrum exhibited a clear pulse peak shift towards higher
APF and reduced power in Q4 (figure 2c). Furthermore, the CDF of temporal APFs contained
significantly (p<0.001) higher values in male patients belonging to Q4 (figure 2d). Median spectrograms
for Sample Entropy Q1 and Q4 indicated higher APF and larger frequency variation in males belonging to
Q4 with significantly higher temporal APF values (p<0.001) (figure 3a, 3b and 3d). The median power
spectrum exhibited only a moderate pulse peak shift towards higher APF but higher power in Q4 (figure 3c).
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FIGURE 2 Comparison of male obstructive sleep apnoea patients in a) the best-performing (Q1, n=88) and b) the worst-performing quartiles (Q4,
n=80) based on lapse count in psychomotor vigilance task. Median spectrograms (colour map represents power of each pulsation frequency) of
males in Q4 exhibit higher arterial pulsation frequency (APF) and variance compared to males in Q1. c) The median power spectrum reveals a
clear pulse peak shift towards higher APF and reduced power in Q4. d) The cumulative distribution function (CDF) of APF with 95% confidence
intervals contains significantly (p<0.001) higher values in males belonging to the worst-performing quartile. The peak-frequency curve indicates
the specific frequency in each segment having the highest power.
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Comparison of female OSA patients in Q1 and Q4 based on lapse count showed that median
spectrograms of females in Q4 exhibit only slightly higher APF compared to female patients in Q1 (figure
4a and b). The median power spectrum showed a moderate pulse peak shift towards higher APF and
reduced power in Q4 (figure 4c). The cumulative distribution of temporal APFs contained significantly
higher values in Q4 than in Q1 (figure 4d). In the comparison between Sample Entropy Q1 and Q4,
median spectrograms and median power spectrums were highly similar (figure 5a–c). However, females in
Q1 had a trend towards slightly higher (p=0.09) temporal APF values in cumulative distribution (figure 5d).
Regression analysis
Based on stepwise regression analyses, median APF was found to be a significant predictor of belonging to
lapses Q4 (β=0.270, SE=0.109, p=0.013) alongside female sex (β=1.286, SE=0.267, p<0.001), t90% (β=0.050,
SE=0.02, p<0.001), age (β=0.031, SE=0.010, p=0.002) and subjective sleepiness (β=0.073, SE=0.024,
p=0.002) (table 3). In contrast, only female sex (β=0.748, SE=0.249, p=0.002) and depression (β=0.906,
SE=0.362, p=0.012) were significant predictors in belonging to Q4 based on Sample Entropy (table 3).
Sleep stage distribution, AHI or arousal index were not associated with increased probability of belonging
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FIGURE 3 Comparison of male obstructive sleep apnoea patients in a) the best-performing (Q1, n=82) and b) the worst-performing quartiles (Q4,
n=82) based on Sample Entropy (SE) in the psychomotor vigilance task. Median spectrograms (colour map represents power of each pulsation
frequency) indicate higher arterial pulsation frequency (APF) and larger variation in males belonging to Q4, together with significantly higher APFs
(p<0.001) in cumulative distribution function (CDF). c) However, the median power spectrum exhibits only a moderate pulse peak shift towards
higher APF and higher power in Q4. The peak-frequency curve indicates the specific frequency in each segment having the highest power. d) CDF
of nocturnal APF.
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Based on models constructed by logistic stepwise regression, ROC curves and AUC values were
determined to evaluate models’ sensitivity and specificity in classifying patients to Q1 and Q4 based on
lapses (figure 6). Univariate models show that median APF and ESS had the best differentiation capability,
however with AUCs of only 0.5960 and 0.6067, respectively. By utilising a multivariate approach including
sex, age, ESS score together with median APF or t90%, AUC reached 0.7314 and 0.7349, respectively
(figure 6). For comparison, AHI was able to differentiate Q1 and Q4 patients with a sensitivity of 65.5%
and specificity of 32.9% with 15 events·h−1 cut-off and was not a significant predictor of belonging to
lapses Q4. In addition, ESS was able to differentiate Q1 and Q4 patients with a sensitivity of 25.6% and
specificity of 81.7% when using a 16-point cut-off.
Discussion
In this study, we compared PPG-derived APF and frequency domain features between OSA patients
within the best and worst PVT performance quartiles. We found increased APF and higher nocturnal
variance of the frequencies in the worst-performing male OSA patients compared to the best-performing
patients. However, differences in PPG features diminished in female patients and were not as clearly
distinguishable. Stepwise regression analysis revealed that higher APF and t90% are associated with a higher
number of lapses in PVT. These results imply that increased APF together with more severe nocturnal
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FIGURE 4 Comparison of female obstructive sleep apnoea patients in a) the best-performing (Q1, n=66) and b) the worst-performing quartiles (Q4,
n=59) based on lapse count in the psychomotor vigilance task. Median spectrograms (colour map represents power of each pulsation frequency)
of females in Q4 exhibit slightly higher arterial pulsation frequency (APF) compared to females in Q1. c) The median power spectrum shows a
small shift towards higher APF in pulse peak location between Q1 and Q4, and reduced power in Q4. d) The cumulative distribution function of
temporal APF with 95% confidence intervals contains slightly (p<0.05) higher values in the worst-performing quartile. The peak-frequency curve
indicates the specific frequency in each segment having the highest power.
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are in line with previous studies, indicating that female sex and older age are independent risk factors for
poor PVT performance.
The frequency content of nocturnal PPG exhibits a clear difference between males in the worst-performing
(Q4) and the best-performing (Q1) quartiles based on both lapses and Sample Entropy. APF was found to
vary more in both Q4s and have significantly higher values compared to Q1s. Furthermore, in lapses Q4s
the increased APF was also observed in the group-median power spectrum together with reduced power of
the peak frequencies (figures 2c and 4c). Higher APF is due to increased heart rate; OSA and intermittent
hypoxaemia (tables 2 and 3) elevate the nocturnal sympathetic activity, heart rate and blood pressure
[22–24]. As seen in table 2, males in lapses Q4 had a minor trend for more severe hypoxaemia together
with shorter total sleep time. However, increase in t90% significantly elevated the odds of belonging to Q4
based on lapses (table 3). Conversely, this was not found in Sample Entropy Q4 despite the higher APF.
Moreover, the association between APF and Sample Entropy diminished in stepwise regression (table 3),
and power reduction of peak frequencies in Q4 was not observed (figures 3c and 5c). This implies that the
spectrograms, which retain the temporal changes in the PPG signal, associate better to the deteriorated
vigilance than median APF. It could also be speculated that there is a substantial inter-individual variation
in cardiac response to hypoxaemia and breathing cessations. Older male patients especially seem to be
vulnerable to nocturnal sympathetic overdrive (table 1), making APF a useful tool for assessment of the
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FIGURE 5 Comparison of female obstructive sleep apnoea patients in a) the best-performing (Q1, n=60) and b) the worst-performing quartiles (Q4,
n=60) based on Sample Entropy (SE) in the psychomotor vigilance task. Median spectrograms (colour map represents power of each pulsation
frequency) indicate similar arterial pulsation frequency (APF) and overall frequency content in both quartiles. c) Furthermore, median power
spectrums exhibit similar pulse peak locations and power. d) In the cumulative distribution function of APFs, the difference was not statistically
significant (p=0.09). The peak-frequency curve indicates the specific frequency in each segment having the highest power.
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TABLE 3 Stepwise regression models for estimated β-coefficients and corresponding odds for
belonging to Q4 instead of Q1
Lapses Sample Entropy
OR β Standard error p-value OR β Standard error p-value
Female sex 3.62 1.29 0.27 <0.01 2.11 0.75 0.25 <0.01





Depression 2.47 0.91 0.36 <0.02
ESS score 1.08 0.07 0.02 <0.02
AHI events·h−1






Median APF min−1 1.31 0.27 0.11 <0.02
This analysis comprises the whole population (n=567), where quartiles are defined for lapses (Q1: 0–4
lapses; Q4: over 35 lapses) and Sample Entropy (Q1: 0–0.12; Q4: over 0.71) separately. Both models are
computed using the logit-link function. Models were constructed using constant starting model, Bayesian
Information Criterion (BIC) as a model entering criterion and treating the response variable as a
categorical variable. All models were constructed by separately inputting investigated
polysomnography-based parameters. Parameters that were excluded from the final regression model
based on BIC are left blank. BMI: body mass index; COPD: chronic obstructive pulmonary disease;
ESS: Epworth Sleepiness Scale; AHI: apnoea–hypopnoea index; t90%: time spent under 90% saturation;
AI: arousal index; N1–N3: non-rapid eye movement sleep stages 1–3; REM: rapid eye movement sleep;



























FIGURE 6 Receiver operating characteristic curves and corresponding area under the curve (AUC) for the
assessment of belonging to the worst-performing quartile based on lapses. Only the significant (p<0.05)
predictor variables, determined in stepwise logistic regression, are used in multivariate and univariate
estimations of models’ sensitivity and specificity. ESS: Epworth Sleepiness Scale; mAPF: median arterial
pulsation frequency; t90%: sleep time with oxygen saturation <90%.
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Analysis comprising only female patients showed smaller differences between best and worst performers in
the frequency content of PPG. Based on previous studies, women tend to perform worse than males in
PVT [10, 18, 25], which was observed in this cohort also (table 1). Women also exhibit a higher resting
heart rate and different cardiac regulation sensitivity [26]. Furthermore, in both Q1 and Q4 women had
substantially milder OSA, longer total sleep time, a larger amount of N3 sleep and less N1 sleep than men
(table 2), which can partly explain the obtained results. Moreover, females had a higher Q4 threshold than
men both in lapses and Sample Entropy as well as significantly higher ESS scores in lapses Q4 (tables 1
and 2). These results indicate a clear difference between men and women in vigilance deterioration and
baseline sleepiness in best- and worst-performing quartiles. This was however expected as we have
previously shown that OSA and OSA-related sleepiness also are sex-dependent [9, 27]. Based on the
current body of evidence regarding the association between OSA and impaired vigilance [7, 8, 10], it could
be speculated that more severe intermittent hypoxaemia, self-reported sleepiness and fatigue, comorbid
depression and older age are better indicators of poor vigilance for female OSA patients than changes in
PPG frequency domain features. The present stepwise regression analyses strongly support this conclusion
(table 3), as female sex and comorbid depression were significant predictors of large within-test variation.
Elevated intermittent sympathetic activity leads to higher blood pressure [22] and further, to higher
nocturnal heart rate [24] which associates to deteriorated vigilance especially in men via increased APF
(figures 2 and 3). One of the reasons behind this association could be sympathetic overdrive and its effect
on haemodynamics and cerebrospinal fluid oscillations in slow-wave (SW) sleep. Recent literature shows
that SW oscillations in N2 and N3 sleep drive the oscillations in cerebral blood volume (CBV) and
cerebrospinal fluid (CSF), enabling protein clearance from the brain via the glymphatic system [28, 29].
Under high blood pressure, the protein clearance process via oscillation of CBV and CSF can be disrupted
and even reversed [28]. In addition, glymphatic propulsion associates with cardiac pulsations and
breathing pulsations [30]. Therefore, untreated OSA as a chronic condition can contribute to the
accumulation of proteins in the brain over time [31–33], and thus, together with hypoxaemia-induced
neuronal brain damage, lead to cognitive decline [10]. In this study, only a minor difference between Q1
and Q4 in the amount of N3 sleep was found (table 2). This implies that higher APF, which is linked to
elevated sympathetic tone and blood pressure, could be a marker for reduced protein clearance during
slow-wave sleep (SWS) irrespective of SWS quantity. Moreover, higher heart rate [16], elevated blood
pressure [34], elevated sympathetic tone [22] and moderate-to-severe OSA [2, 35] are associated with
comorbid cerebral small vessel disease, which could also explain the poor vigilance in male patients having
higher APF (figures 2 and 3). To test this hypothesis, a large prospective study combining current protocol
with PPG analysis within different sleep stages, MR imaging and CSF protein analysis is warranted.
It is noteworthy that the presented method does not include the exact detection of pulse peaks in PPG for
pulse detection. This is, however, advantageous as PPG waveforms are in part modulated by the
functioning of the aortic valve and mechanical properties of the arteries that carry the pulse wave. In
addition, the computation of spectrograms and spectrums is fast and convenient; the presented scheme
can be easily implemented in existing diagnostic methods such as PSG or home sleep apnoea testing.
These findings together with previous studies imply that the assessment of OSA severity and evaluation of
related daytime dysfunctions could be conducted using pulse oximeter measurements and deep learning
[9, 10, 36]. This would further facilitate referrals to in-depth examinations for those with the highest risk
of severe consequences of OSA. To assess specifically the risk of deteriorated vigilance, we compiled
univariate models for the three most important predictors (ESS score, t90% and median APF) of belonging
to the lapses Q4 and also different combinations of the multivariate models (figure 6). The ROC analyses
revealed that none of the three parameters are capable of producing meaningful predictions alone and
suffer from a high number of false positives with high sensitivity. However, when median APF, ESS or t90%
are combined with sex and age, models’ sensitivity and specificity outperform the univariate models and
the differentiation capability of the AHI (figure 6). However, to produce a more reliable model, similar
analyses need to be conducted in various patient cohorts to optimise the used predictor variables and
related β-coefficients.
This study has certain limitations. First, the median total sleep times were short, which is most likely due
to a common first-night effect in PSG. It is acknowledged that for a more comprehensive analysis,
nocturnal PPG recordings from multiple nights would be needed. However, the current protocol
consisting of PVT prior to PSG mitigates the first-night effect to PVT results. Second, our data do not
include a sleep diary or long-term actigraphy. Chronic sleep deprivation is shown to affect the PVT
performance to a large extent [37]; therefore, the lack of these data is a limitation. Third, we could not
consider motivational aspects affecting PVT performance such as having a driver’s licence or being a
professional driver. These factors also affect the ESS scores, and we acknowledge that this is a limitation.
Fourth, a complete record of the patients’ medication at the time of measurement was not available. It is
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acknowledged that, for example, psychoactive medication can affect the PVT results and medications such
as β-blockers can affect the arterial pulsation waveforms. We minimised this effect in stepwise regression
by adjusting for comorbidities, but we acknowledge that this is a limitation. Fifth, the existence of
hypertension is based on medical records and earlier diagnosis. Thus, this cohort may contain patients
with undiagnosed arterial hypertension. In addition, hypertension was treated as a dichotomous variable
due to the lack of blood pressure follow-ups of the patients in this cohort. Sixth, besides PVT, other
concentration and sleepiness tests such as the Oxford Sleep Resistance (OSLER) test and Maintenance of
Wakefulness test exist. By combining these tests with the PVT, a more comprehensive overview of the
patients’ daytime performance and symptoms would be achieved.
In conclusion, an APF shift to higher frequencies and increased median frequency of the PPG provide a
PSG marker for poor psychomotor vigilance task performance in male OSA patients. These findings
highlight the connection of sleep disorders to cardiorespiratory regulation. In addition, the presented
method could help in detecting those OSA patients at the highest risk of deteriorated vigilance.
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